$ADM

CJ CheilJedang and ADM to Form New Joint Venture to Strengthen Amino Acid Production and Supply Chains

CJ CheilJedang (KRX: 097950) and ADM (NYSE: ADM) plan to form a joint venture to produce and market amino acids for livestock. The venture will use CJ's facilities in Iowa and Brazil, ADM's plant in Illinois, and CJ's IP. CJ will own a majority stake, aiming to strengthen U.S. production and global supply chains.

Original reporting
Published Oct 5, 2026, 4:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 9:06 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
CJ CheilJedang and ADM to Form New Joint Venture to Strengthen Amino Acid Production and Supply Chains — source image
Decision brief

The 30-second read

$ADMBullishMed
01

Why it matters

The joint venture creates a new revenue stream for ADM and leverages CJ's fermentation technology, potentially improving margins and supply security in the feed industry.

02

Market read

The deal adds strategic depth to ADM's portfolio and may positively affect its stock, while highlighting growing collaboration in the global food‑security space.

03

What to watch

Regulatory approvals and integration of CJ's IP may take longer than expected, delaying benefits

Relevance 8/10Novelty 8/10Timing: immediate announcement

Background

ADM (NYSE:ADM) is a leading global agribusiness; CJ CheilJedang (KRX:097950) is a major Korean food and biotech firm. The partnership aims to secure a reliable supply of lysine and other amino acids for livestock feed.

Company-level read

Ticker impact

$ADMBullishHigh confidence
Context

ADM announced a joint venture with CJ CheilJedang to produce and market feed‑grade amino acids in the U.S., creating a new business unit.

Expected impact

likely modest upside as the market prices in added growth and cost‑efficiency from the partnership

Evidence & confidence

ADM is a large, diversified agribusiness; a strategic JV that secures supply and expands product offering is viewed as a positive catalyst.

Market effects

strengthens the animal‑nutrition and feed‑additive sector by consolidating supply chains

supports U.S. domestic amino‑acid production and may reduce reliance on imports

signals increased collaboration between Asian and U.S. agribusinesses, potentially influencing global feed‑grade amino‑acid pricing

Counterpoint

The JV could dilute ADM's focus on core commodities and expose it to execution risk in a niche market

Key entities

  • ADM

    U.S. agribusiness and feed‑additive producer

  • CJ CheilJedang

    Korean food and biotech company with fermentation expertise

Related articles

$ADMMed

CJ CheilJedang partners with ADM to boost U.S. lysine output amid China curbs

CJ CheilJedang (097950) and ADM formed a joint venture to boost U.S. lysine production, with CJ holding a 63% stake. The move aims to compete with Chinese lysine amid tightened trade restrictions. CJ will contribute its U.S. and Brazil facilities, while ADM will provide its Illinois plant and raw material network. Lysine prices have rebounded due to trade actions against China, with U.S. prices up 38% since December.

$ADMMed

Amino Acids Venture Might Change The Case For Investing In ADM Stock

Archer-Daniels-Midland (ADM) and CJ CheilJedang formed a joint venture to produce and sell feed-grade amino acids in the Americas. The deal, with CJ as majority owner, includes ADM's Decatur facility. Analysts expect ADM's revenue to grow 2.8% annually to $89.2B by 2029, with earnings rising to $2.3B. The joint venture is part of ADM's broader strategy to focus on fermentation-based offerings and animal nutrition.

$ADMMedAI 8/10

CJ CheilJedang and ADM form amino acid joint venture

CJ CheilJedang (KRX:097950) and ADM (NYSE:ADM) agreed to form a joint venture to produce and market feed-grade amino acids in the Americas. CJ will license its technology and hold majority ownership. The venture will use facilities in Iowa, Illinois, and Brazil, aiming to enhance cost competitiveness and support U.S. production.

$ADMMed

ADM’s Infant Probiotic Trial: A New Data Catalyst In Consumer Health

Archer-Daniels-Midland (ADM) completed a clinical trial testing a probiotic for infant colic relief. The double-blinded, placebo-controlled study aims to support ADM's position in science-backed nutrition. Positive results could boost ADM's pediatric nutrition sales and stock sentiment. The trial was updated on September 22, 2026, with data analysis underway.

$CNCMed

2 Non-AI Giants to Buy on Solid Guidance and Lucrative Valuation

Centene Corp. (CNC) and Archer-Daniels-Midland Co. (ADM) are highlighted for strong performance and attractive valuations. CNC expects 2026 revenues of $173-$177B and adjusted EPS over $4.80, with a forward P/E of 13.58X. ADM raised 2026 adjusted earnings guidance to $5.15-$5.60 per share, with a forward P/E of 16.60X.

$ADMMedAI 8/10

SEC Produces 307,000 Documents in Fraud Case Against Former ADM CFO

The SEC has produced 307,000 documents in its fraud case against former ADM CFO Vikram Luthar, with ongoing document production. The case involves alleged inflation of ADM's Nutrition business performance. ADM settled related charges with a $40M penalty. Discovery is expected to continue until March 2027. Luthar is contesting the allegations in court.